Clovis Jumps as Cancer Drug Gets Priority for FDA Review

Clovis Oncology Inc. shares soared after the U.S. Food and Drug Administration granted a faster review process to the company’s experimental ovarian cancer drug rucaparib.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.